Literature DB >> 23428863

The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection.

Mutsuko Minata1, Kouji H Harada, Masatoshi Kudo, Iwao Ikai, Naoshi Nishida.   

Abstract

OBJECTIVES: Hepatocellular carcinoma (HCC) frequently recurs even after curative resection. The purpose of this study was to identify factors predictive for postoperative recurrence of HCC in patients who underwent curative resection using immunohistochemistry.
METHODS: Expression of vascular endothelial growth factor (VEGF), E-cadherin and cyclin D1 in HCC tissue were analyzed for 133 HCC patients who underwent curative resection of tumors using immunohistochemical analysis. Relationships of expressions and disease-free survival of HCC were evaluated using univariate and multivariate analyses.
RESULTS: The average period of follow-up of the patients was 6.7 years. Multivariate analyses revealed that only strong expression of VEGF in HCC tissue was significantly associated with metastatic recurrence (p < 0.001, hazard ratio, HR, 3.32).
CONCLUSIONS: Evaluating VEGF in HCC tissue after surgical resection has predictive value for metastatic HCC recurrence. The ability to risk stratify should improve the treatment strategies after hepatectomy.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428863     DOI: 10.1159/000345894

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  6 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis.

Authors:  Ping Zhan; Qian Qian; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-06       Impact factor: 7.293

3.  Intermediate hepatocellular carcinoma: the role of transarterial therapy.

Authors:  Fabrizio Chegai; Antonio Orlacchio; Stefano Merolla; Serena Monti; Lorenzo Mannelli
Journal:  Hepat Oncol       Date:  2015-10

4.  Repeated Transarterial Chemoembolization with Degradable Starch 
Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Simona Francioso; Stefano Merolla; Serena Monti; Mario Angelico; Giuseppe Tisone; Lorenzo Mannelli
Journal:  Curr Med Imaging Rev       Date:  2018-08

5.  Trans-Arterial Chemoembolization with 50 μm Degradable Starch Microspheres Versus 300-500 μm Drug Eluting Beads in Hepatocellular Carcinoma: A Comparative Analysis of Initial Treatment Outcomes.

Authors:  Isil Yildiz; Sinan Deniz; Ali Ozer; Kosti Caliskan
Journal:  J Belg Soc Radiol       Date:  2022-03-10       Impact factor: 1.894

Review 6.  Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy.

Authors:  Shao-Li Huang; Yu-Ming Wang; Quan-Yue Wang; Guang-Gui Feng; Fu-Qing Wu; Liu-Ming Yang; Xi-He Zhang; Hong-Wu Xin
Journal:  Front Genet       Date:  2021-07-08       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.